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Background. Survival after myeloablative therapy followed
by hematopoietic cell transplant (HCT) is limited by substantial
treatment-related toxicities. Acute renal failure (ARF) devel-
ops in 25% to 50% of patients after HCT.
Methods. One hundred forty-seven patients were followed
prospectively from time of transplant. ARF was defined as a
doubling of baseline serum creatinine at any time during the first
100 days post-transplant. We conducted a nested case-control
study to identify precipitants of ARF. For each person who de-
veloped ARF, 2 controls were selected at random from patients
who had not developed ARF as of that time. An exposure pe-
riod was defined for each case as the 2 weeks prior to the day
on which the matched case met the criteria for ARF. The risk of
ARF in relation to demographic and anthropometric character-
istics, and to types of treatment and comorbidity, was examined
using univariable and multivariable conditional logistic regres-
sion models. Odds ratios for the associations with ARF were
estimated, taking into account the matching.
Results. Fifty-three patients (36%) developed ARF at a me-
dian of 33 days after transplant (range 1 to 97). Elevated risks
were observed in patients who received liposomal amphotericin
(OR 6.58; 95%CI 1.45–29.95) and conventional (OR 3.60;
95%CI 0.79–16.55), and in those patients with sinusoidal ob-
struction syndrome (SOS) (previously termed veno-occlusive
disease) (OR 9.37; 95%CI 2.29–38.38). For every 0.1 mg/dL in-
crease in baseline serum Cr, the risk of ARF decreased by 30%.
Neither total body irradiation (TBI) dose, levels of metabo-
lites of cyclophosphamide, sepsis, acute graft versus host disease
(GVHD), nor cyclosporine (CSA) levels was associated with an
increased risk of ARF.
Conclusion. The cumulative incidence of ARF after HCT
remains high. Amphotericin use during the 2-week exposure
period and presence of hepatic sinuosoidal injury increased the
risk of ARF within the first 100 days after HCT. Higher levels of
serum creatinine at baseline were associated with a lower risk
of ARF.
Key words: acute renal failure, hematopoietic cell transplant, myeloab-
lative conditioning therapy, risk factors.
Received for publication May 13, 2004
and in revised form July 15, 2004
Accepted for publication July 27, 2004
C© 2005 by the International Society of Nephrology
High-dose myeloablative therapy followed by
hematopoietic cell transplant (HCT) is an increasingly
utilized treatment for many malignancies, aplastic
anemias, and certain inborn errors of metabolism.
However, patient survival may be limited by substantial
treatment-related toxicities. Among the most severe
of these toxicities is acute renal failure (ARF), which
occurs frequently in the first 100 days following HCT.
Mortality rates among transplanted patients with renal
disease in this setting are higher than among those who
retain normal renal function [1–4].
In 2 large retrospective reviews of patients undergo-
ing HCT in the 1980s, the frequency of ARF (defined as
a doubling of baseline serum creatinine within the first
30 days post-transplant) was 26% of 275 patients and
53% of 272 patients, respectively [1, 2]. Identified risk
factors included sinusoidal obstruction syndrome, older
age, jaundice, weight gain, and exposure to amphotericin
B [1, 2]. In a more recent study, hepatic toxicity, sinusoidal
obstruction syndrome, and lung toxicity were associated
with an increased risk of ARF [4]. The conditioning regi-
men of cyclophosphamide and total body irradiation has
also been implicated in pediatric studies [3, 5]. There is
variable metabolism of cyclophosphamide between pa-
tients resulting in varying concentrations of metabolites,
some of which may damage renal tubular cells in culture
and deplete these cells of thymidine, a nucleotide needed
for repair [6].
Since the 1980s, there have been many advances in
hematopoietic cell transplantion, including more accu-
rate human lymphocytic antigen (HLA) matching of
donor and recipient, more effective strategies of infec-
tion prophylaxis, a change from the use of conventional
amphotericin to liposomal formulations, and an overall
reduction in the intensity of myeloablative conditioning
regimens. We studied a more recent cohort of patients
transplanted with allogeneic donor cells following a uni-
form conditioning regimen of cyclophosphamide (CY)
and total body irradiation (TBI) to determine the in-
cidence of and risk factors related to the development
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of ARF. We used a nested case-control study design, in
which the 14 days prior to the development of ARF was
defined as the exposure period in which clinical data and
time-related risk factors were ascertained.
METHODS
Between April 1997 and January 2000, all patients
at the Fred Hutchinson Cancer Research Center with
a hematologic malignancy undergoing allogeneic trans-
plantation after a conditioning regimen of CY and TBI
were invited to participate in this study. One hundred
forty-seven patients agreed to participate, and signed in-
formed consent forms were approved by the Institutional
Review Board. The patients included in this nested case-
control study were selected from the cohort of 147 pa-
tients, as described below.
Technique of hematopoietic cell transplantation
Seven days prior to the infusion of stem cells, 60 mg/kg
body weight of CY was given through a central venous
access catheter over 1 to 2 hours. On the following day,
a second infusion of the same dose of CY was given.
The pharmacokinetics of CY in this cohort of patients
has been published [7]. After a day of rest, TBI (9–
14.2 Gy) was administered in hyperfractionated doses
from opposing cobalt sources on each of the 3 or 4 sub-
sequent days. The kidneys were not shielded. Prophy-
laxis regimens against graft-versus-host disease included
cyclosporine or tacrolimus and methotrexate in the ma-
jority of patients, or variations on the above, including
prednisolone and BC3; BC3 is a murine antibody specific
for human CD3. Donor hematopoietic cells were infused
on day “zero;” by convention, all subsequent days are
numbered from this day. Infection prophylaxis included
fluconazole or itraconazole, acyclovir, and trimethoprim-
sulfamethoxazole.
Study design
We used a nested case-control study design to explore
risk factors for ARF, defined as a doubling of baseline
serum creatinine within the first 100 days after transplant.
Baseline serum creatinine was the value obtained prior
to the start of myeloablative conditioning therapy. Two
controls were selected at random from among patients in
the study cohort who were event-free for at least as long
as the time preceding the onset of ARF in the matched
case. An exposure period of 2 weeks prior to the onset
of ARF was defined, in which potential time-varying risk
factors were examined. The exposure period for a control
patient was defined as the 2 weeks prior to the study day
on which the matched case developed ARF. Thus, 53 cases
and 106 control observation periods comprised the study
population.
The following clinical data were collected during the
14 day exposure periods: daily weight, first morning pulse
and blood pressure, maximum daily temperature, daily
medications, total serum bilirubin, the presence of bac-
teremia or fungemia, and cyclosporine blood levels. In
addition to time-dependent factors, we examined the fol-
lowing pretransplant patient characteristics for their asso-
ciation with ARF: age, gender, baseline serum creatinine
(Cr), weight, and serum albumin, as well as transplant-
related factors such as TBI dose and cyclophosphamide
(CY) metabolite exposure. The occurrence of acute graft
versus host disease (GVHD) and sinusoidal obstruction
syndrome (SOS) developing any time prior to the onset
of ARF in the index case were also examined as potential
risk factors.
Variations in the metabolism of CY were analyzed as
areas under the curve (AUCs) as previously described [7].
AUCs for each of the metabolites of CY [O-carboxyethyl
phosphoramide mustard (CEPM), deschloroethyl-cyclo-
phosphamide (DCCY), hydroxypropyl-phosphoramide
mustard (HPPM), 4-ketocyclophosphamide (KetoCY),
and 4-hydroxy cyclophosphamide (HCY) [7]] were cal-
culated based on their plasma levels. TBI was analyzed
by total dose: 9 Gy, 12 Gy, and ≥13.2 Gy. During the 2-
week exposure period, the mean pulse, systolic and dias-
tolic blood pressure measurements, and change in weight
from baseline to time of ARF were evaluated as predic-
tors. Hypertension was defined in adults as 3 instances
of either a systolic measurement ≥140 mm Hg or a di-
astolic measurement ≥90 mm Hg in the exposure pe-
riod. In pediatric patients, hypertension was defined as
3 measurements ≥95th percentile for age and height as
standardized and described elsewhere [8]. Fever was de-
fined as any daily temperature ≥38 degrees Celsius. Bac-
teremia/fungemia was defined as the presence of at least 1
positive blood culture during the exposure period. Med-
ications taken during the exposure period were divided
into the broad categories of immunosuppression, antibi-
otics, diuretics, and antihypertensives, and these cate-
gories were analyzed separately. Nephrotoxic antibiotics
analyzed individually included amphotericin, liposomal
amphotericin (Abelcept; The Liposome Co., Princeton,
NJ, USA), vancomycin, and gentamicin. Sinusoidal ob-
struction syndrome was defined based on the triad of hep-
atomegaly, weight gain, and jaundice [9]. The severity of
SOS was classified as mild, moderate, or severe, based on
symptom resolution and treatment required [10]. Acute
GVHD was graded I-IV based on the Glucksberg classi-
fication as modified by a working group [11].
Statistical methods
The distributions of the continuous covariates in the
cases and controls were compared using Wilcoxon rank
sum tests. The odds ratios (OR) were calculated us-
ing conditional logistic regression models, which take
into account the matching. All potential predictors were
first evaluated in univariable conditional logistic regres-
sion models. Those parameters reaching a univariable
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significance level of P ≤ 0.1 were assessed for significance
in multiple conditional logistic models. The P values cor-
responding to the multiple regression model are based
on the Wald test. All analyses were performed using SAS
statistical software (Cary, NC, USA).
RESULTS
The demographic characteristics of the study cohort
have been described previously [7]. All patients received
allografts, the majority (70%) for CML. One hundred
thirty-nine patients (95%) received hematopoietic cells
derived from HLA-matched unrelated donors. The me-
dian age at transplant was 37 years with a range of 3–
58 years of age. Of 147 patients, 53 (36%) developed
ARF before day +100, at median day +33 (range day
+1 to +97) after transplant.
Table 1 lists the median and ranges for the risk fac-
tors analyzed and modeled as continuous variables con-
sidered among cases and controls, and also shows the
univariable associations between ARF and all the po-
tential risk factors. The largest ORs were observed in
patients who received either conventional or liposomal
amphotericin (OR 5.87, 95% CI 2.33–14.79) in the 14-day
exposure period prior to development of ARF, and in
those who had a clinical diagnosis of moderate or se-
vere SOS prior to the date of onset of ARF (OR 5.19,
95% CI 1.86–14.43). There was no difference in size of
the increased risk of ARF associated with the receipt of
conventional versus liposomal amphotericin (OR 5.0 vs.
5.2, respectively). The risk of ARF appeared to be sub-
stantially lower in adults than children (OR 0.21, 95% CI
0.07–0.66). The risk of ARF was also associated with a
5% greater gain in weight from baseline (initial weight at
clinic visit prior to the start of cyclophosphamide) to the
end of the exposure period (OR 1.37, 95% CI 1.05–1.78).
Higher levels of baseline serum creatinine were associ-
ated with a reduced risk of ARF (0.83 per 0.1 mg/dL,
95% CI 0.73–0.94). Exposure to metabolites of CY dur-
ing conditioning therapy was not associated with an in-
creased risk of ARF. Similarly, higher doses of TBI and
higher CSA levels did not appear to increase the risk of
ARF in these patients.
Many of these factors were inter-related. For exam-
ple, younger patients were more likely to receive ampho-
tericin, and were less likely to have developed moderate
or severe SOS. Those patients with the largest weight
gain from baseline to the onset of ARF were more likely
to have SOS and to have received amphotericin. In a
multiple regression model adjusted for age and gender
(Table 2), the OR for ARF associated with having re-
ceived liposomal amphotericin during the 2-week expo-
sure period was 6.5 (95% CI 1.45–29.95). Patients who re-
ceived conventional amphotericin also had an increased
risk of ARF (OR 3.6, 95% CI 0.79–16.55). Similarly, pa-
tients with moderate or severe SOS were more likely
to develop ARF than patients without SOS or those
with mild SOS (OR 9.37, 95% CI 2.29–38.38). For every
0.1 mg/dL increment in baseline serum creatinine, the OR
for ARF was reduced by approximately 30% (95% CI
0.56–0.88). There was little difference in the risk of ARF
between adults and children after adjusting for ampho-
tericin use, SOS, and baseline serum creatinine (OR 0.79;
95% CI 0.14–4.40). The association between a weight gain
of >5% and ARF was confounded by amphotericin use,
and SOS and was not a predictor of ARF after adjust-
ing for these factors (OR 1.13, 95% CI 0.83–1.55). Ad-
justed ORs for the remaining variables in Table 1 were
calculated and were not appreciably different from the
univariable ORs (data not shown).
DISCUSSION
Acute renal failure, defined as a doubling of baseline
serum creatinine, remains common after HCT. In spite of
recent advances in the care of patients undergoing HCT,
the cumulative incidence of ARF was 36% in this cohort.
Two major factors associated with an increased risk of the
development of ARF were identified by multivariable
analysis: amphotericin use and the presence of moder-
ate or severe SOS. There was no evidence in the data that
the incidence of ARF was related to TBI dose, cyclophos-
phamide metabolite exposure levels, sepsis, GVHD, cy-
closporine levels, weight gain, and older age.
Unlike previous studies of ARF after HCT, all of our
patients received the same conditioning regimen, allow-
ing us to cleanly evaluate dosage of TBI as a risk fac-
tor. This is also the first study to investigate levels of
metabolites of cyclophosphamide as potential media-
tors of renal injury. Though other studies have looked
at any cyclosporine use, we investigated blood levels
of cyclosporine in relation to the occurrence of ARF.
Although much of the renal toxicity of cyclosporine is
thought to be dose dependent [12], we found that higher
levels of cyclosporine were not associated with an in-
creased risk of ARF in this patient population. However,
in children, cyclosporine levels above 200 lg/L have been
associated with an increased risk of ARF [13].
Our data suggest that an elevated baseline serum crea-
tinine was associated with a reduced risk. It is conceivable
that this association is in part an artifact of our definition
of ARF (at least a doubling of baseline serum creatinine
level) because the absolute change required to meet the
criterion is less for a person with a low baseline level than
a higher one. However, a possible basis for this reduced
risk being genuine is suggested by experimental animal
data showing increased cholesterol in renal tubular cells
at times of systemic stress or direct tubular injury [14,
15]. Increased levels of cholesterol in renal tubular cells
confer a “cytoresistant” state potentially protecting the
kidney from further injury and the development of ARF
[14, 15]. This cytoresistant state can persist for a variable
length of time after the initial injury [14]. Thus, to the ex-
tent that a high baseline serum creatinine reflects earlier
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Table 1. Odds ratio of renal insufficiency with 95% confidence intervals
Factor Controls Median range Cases Median range Odds ratio
Pretransplant characteristics
Age years
4–17 6 11 1.0
18–55 100 42 0.21 (0.07–0.66)
Gender
Female 45 20 1.0
Male 61 33 1.22 (0.62–2.40)
Serum creatinine (×0.1 mg/dL) 106 1.0 (0.3–1.4) 53 0.9 (0.2–1.4) 0.83 (0.73–0.94)
GFR (×10 mg/dL) 106 86 (51–223) 53 104 (47–363) 1.16 (1.06–1.27)
Serum albumin mg/dL 105 4.1 (2.4–4.8) 52 4.0 (3.0–4.9) 0.47 (0.18–1.22)
TBI Gy
9 or 12 49 21 1.0
13.2 or 14.4 57 32 1.31 (0.67–2.56)
AUC–CY (×100) 106 6085 (3647–8271) 53 6246 (2767–8546) 1.01 (0.98–1.04)
AUC–HCY (×100) 106 154 (59–283) 53 138 (61–298) 0.57 (0.30–1.10)
AUC–CEPM (×100) 104 379 (118–706) 53 424 (118–1881) 1.14 (0.94–1.38)
AUC–DCCY (×100) 106 470 (210–1685) 53 588 (264–1619) 1.08 (0.94–1.24)
AUC–KetoCY (×100) 106 227 (83–648) 53 211 (85–648) 1.04 (0.73–1.48)
AUC–HPPM (×100) 87 69 (14–471) 52 66 (18–1051) 1.07 (0.77–1.48)
AUC–PM (×100) 104 1013 (346–4162) 53 966 (486–7019) 1.01 (0.97–1.05)
Medications during exposure period
Antihypertensives
No 40 18 1.0
Yes 66 35 1.20 (0.58–2.49)
Diuretics
No 78 32 1.0
Yes 28 21 2.22 (0.98–5.05)
Amphotericin ABLC
No 102 43 1.0
Yes 4 10 5.00 (1.57–15.94)
Amphotericin B
No 101 40 1.0
Yes 5 13 5.20 (1.85–14.59)
Gentamicin
No 98 48 1.0
Yes 8 5 1.34 (0.37–4.93)
Vancomycin
No 79 32 1.0
Yes 27 21 1.90 (0.94–3.83)
Clinical characteristics during exposure period
Pulse (×10) 104 91 (65–118) 52 92 (73–125) 1.24 (0.93–1.65)
Hypertension
No 53 29 1.0
Yes 53 24 0.81 (0.40–1.63)
Systolic BP (×10) 106 126 (98–146) 53 124 (97–151) 0.86 (0.63–1.17)
Diastolic BP (×10) 106 80 (51–95) 53 76 (57–96) 0.65 (0.42–1.01)
Pulse pressure (×10) 106 45 (28–69) 53 47 (32–75) 1.12 (0.76–1.66)
Fever
No 56 28 1.0
Yes 49 25 1.03 (0.48–2.19)
High temperature (◦C) 105 37 (36–39) 53 37 (36–39) 1.98 (0.98–4.01)
Total bilirubin 106 1.9 (0.4–21.6) 52 1.6 (0.5–35.2) 1.04 (0.96–1.14)
Infection
No 92 44 1.0
Yes 14 9 1.41 (0.53–3.77)
Weight change (>5%) 105 53 1.37 (1.05–1.78)
Cyclosporine level (×100) 99 500 (131–1803) 51 422 (89–1572) 0.95 (0.86–1.04)
Clinical events before case time
SOS
None, mild, or other diagnosis 98 38 1.0
Moderate or severe 8 15 5.19 (1.86–14.43)
Acute GvHD
Grade 0, I, or II 91 42 1.0
Grade III or IV 14 10 1.49 (0.60–3.70)
injury, patients with such levels would truly be at rela-
tively low risk of ARF. However, Zager et al [2] found
a high baseline serum creatinine (>0.7 mg/dL) was inde-
pendently associated with the development of dialysis-
requiring ARF. The differing results between this study
and the present one may be secondary to the choice of
baseline serum creatinine. Zager et al used serum creati-
nine on the day of transplant for this purpose, but this cre-
atinine measurement may reflect changes caused by the
conditioning regimen and/or hydration during the time
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Table 2. Odds ratios of renal insufficiency from a multiple regression
model, adjusted for age (<18 vs. ≥18 years) and gender
Factor Odds ratio 95% CI P value
Amphotericin ABLC 6.58 1.45–29.95 0.01
Amphotericin B 3.60 0.79–16.55 0.10
SOS (moderate or severe) 9.37 2.29–38.38 0.002
Serum creatinine 0.70 0.56–0.88 0.002
before transplant. Similarly, in the pediatric population,
high pretransplant serum creatinine has been associated
with an increased risk of renal failure in the first 3 months
after transplant [16]. Differences in the findings of our
study may also stem from the fact that all of our patients
underwent uniform conditioning regimen and received
allogeneic stem cell transplants.
Previous studies in adults have identified SOS or ele-
vated serum bilirubin levels (used as a surrogate marker
for liver injury) as risk factors for the development of
ARF [1, 2, 4]. In our study, the presence of SOS was as-
sociated with an increase in the risk of ARF. There is
a well-known association between sinusoidal liver injury
and renal insufficiency in patients after hematopoietic cell
transplant [10]. It has been postulated that portal hyper-
tension resulting from hepatic sinusoidal injury leads to
both decreased renal perfusion [9] and tubular injury [17],
the former probably being the more important in the gen-
esis of ARF.
Weight gain was highly correlated with SOS. Weight
gain can be a result of portal hypertension, leading to de-
creased renal perfusion and sodium avidity that precedes
the development of ARF. Thus, weight gain likely serves
as a marker of impending renal injury rather than be-
ing the result of renal injury. Zager et al identified weight
gain within the first 21 days post-transplant as a risk factor
for the development of ARF and ARF requiring dialysis.
Weight gain of ≥10% of baseline at the onset of dialy-
sis for ARF in pediatric stem cell transplant patients was
associated with persistence of renal failure [3]. Though
some have advocated keeping weight gain per se to a min-
imum (<10% fluid overload) to improve outcomes in this
patient population [18], it is unclear if the weight gain is
causal or the result of other insults to these patients. Thus,
prevention of SOS may be the more important strategy.
The reported prevalence of thrombotic microangio-
pathic (TMA) syndromes [hemolytic uremic syndrome
(HUS) and thrombocytopenic purpura (TTP)] ranges
from 2% to 21% after HCT [19–21]. The clinical spec-
trum of renal dysfunction in HCT patients with TMA
varies from an indolent course resulting in chronic renal
insufficiency to fulminant disease with acute renal fail-
ure and death. Several risk factors for TMA have been
proposed: unrelated donor stem cell source [21]; condi-
tioning with TBI [22–24]; age and female gender [19];
and cyclosporine exposure [20, 25–29]. We were unable
to evaluate the presence of TMA or isolate it as a risk
factor for the development of ARF in our patient popu-
lation because lactate dehydrogenase (LDH) levels were
not routinely measured.
The finding of a sharply increased risk of ARF among
patients receiving amphotericin is not surprising because
the nephrotoxicity of conventional amphotericin is well
known [30–33], as is its association with renal failure in the
HCT population [2, 5]. What was surprising was the find-
ing that liposomal preparations were also associated with
an increased risk in this patient population. In studies con-
ducted in febrile neutropenic patients, significantly fewer
patients on liposomal amphotericin experienced nephro-
toxicity (defined as doubling of baseline serum creatinine
or creatinine >3.0 mg/dL) than patients on conventional
amphotericin [34, 35]. In a subset analysis of the allo-
geneic hematopoietic cell transplant recipients, Cagnoni
et al found that those receiving liposomal amphotericin
were less likely to develop nephrotoxicity compared
to those who received conventional amphotericin, 32%
versus 66%, respectively, and fewer patients in the li-
posomal group required dialysis [36]. In a prospective,
randomized controlled trial involving non-HCT intensive
care unit patients with candidal infections, Sorkine et al
found that 66.7% of patients treated with conventional
amphotericin experienced an increase in their serum cre-
atinine compared to 4% of patients in the group treated
with liposomal amphotericin [37]. In our study, the num-
ber of patients receiving amphotericin was small, and
preferential administration of either formulation to pa-
tients otherwise at high risk of ARF could have occurred.
However, we found no difference in the baseline serum
creatinine between patients treated with conventional or
liposomal amphotericin, in the receipt of other nephro-
toxic antibiotics such as vancomycin or gentamicin, or in
other indications for use. The majority of patients were
placed on amphotericin, conventional or liposomal, for
fever of unclear etiology, documented fungal infection, or
history of fungal infection. Given the marked increase in
risk of ARF in patients who received either conventional
or liposomal amphotericin, we recommend that patients
with fever after HCT be treated with amphotericin only if
documented fungal or mold infection exists or there has
been prolonged use of prophylactic triazoles. The preva-
lence of fungal and mold infections in our cohort was
22% and 6%, respectively. Fortunately, newer antifungal
drugs such as fluconazole, itraconzole, voriconazole, and
caspofungin are now available for some indications for-
merly covered by amphotericin. Depending on the end
points chosen, each of these medications has been shown
to be equally efficacious as amphotericin but with better
safety profiles [38].
CONCLUSION
This study found that ARF remains a common prob-
lem after myeloablative HCT, affecting 36% of patients.
In a multivariable analysis, 2 strong risk factors were
identified: use of any amphotericin formulation and the
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presence of moderate or severe SOS caused by the condi-
tioning regimen. Prevention, early recognition, and treat-
ment of SOS, and limiting exposure to amphotericin will
offer the best chance to preserve renal function in patients
after HCT.
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